New Issue: Science’s Impossible Questions. Read Now

World Health Org Calls for Early Treatment for Everyone with HIV

Everyone with HIV should be given antiretroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the WHO said

Illustration of retroviruses.

©iStock.com

Join Our Community of Science Lovers!

By Stephanie Nebehay

GENEVA (Reuters) - Everyone with HIV should be given antiretroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the World Health Organization (WHO) said on Wednesday.

Recent clinical trials have confirmed that early drug use extends the lives of those with HIV and cuts the risk of disease transmission to partners, the WHO said in a statement setting out the new goal for its 194 member states.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Under previous WHO guidelines, which limited treatment to those whose immune cell counts had fallen below a certain threshold, 28 million people were deemed eligible for antiretroviral therapy (ART).

All people at "substantial" risk of contracting HIV should also be given preventive ART, not just men who have sex with men, the WHO said.

The new guidelines are a central plank of the United Nations agency's aim to end the AIDS epidemic by 2030.

"Everybody living with HIV has the right to life-saving treatment. The new guidelines are a very important step towards ensuring that all people living with HIV have immediate access to antiretroviral treatment," said Michel Sidibe, executive director of UNAIDS.

"According to UNAIDS estimates, expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS-related deaths and 28 million new infections by 2030."

The move will lead to a sharp increase in demand for ART medicines, which are typically given as a three-drug cocktail to avoid the risk of the virus developing resistance.

Major suppliers of HIV drugs include Gilead Sciences, ViiV Healthcare, which is majority-owned by GlaxoSmithKline, and multiple Indian generic manufacturers.

The medical charity Medecins Sans Frontieres (Doctors Without Borders) welcomed the WHO's "treat-all" plan, which it believes will prevent many HIV-positive people in poorer countries from falling through the treatment net.

MSF said its experience showed that a third of people who were diagnosed with HIV, but not eligible to start treatment, never returned to the clinic.

The charity also warned that making the new recommendation a reality would require dramatically increased financial support from donors and governments.

The WHO estimates that by 2020 low- and lower-middle income countries will need $18.4 billion annually for the expanded HIV fight. However, fast-tracking the response should yield economic returns of $15 per dollar invested, based on improved health and infections averted.

Since it began spreading 30 years ago, AIDS has killed around 40 million people worldwide.

 

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe